Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays
Top Cited Papers
Open Access
- 6 May 2020
- Vol. 12 (5), 513
- https://doi.org/10.3390/v12050513
Abstract
SARS-CoV-2 enters cells using its Spike protein, which is also the main target of neutralizing antibodies. Therefore, assays to measure how antibodies and sera affect Spike-mediated viral infection are important for studying immunity. Because SARS-CoV-2 is a biosafety-level-3 virus, one way to simplify such assays is to pseudotype biosafety-level-2 viral particles with Spike. Such pseudotyping has now been described for single-cycle lentiviral, retroviral, and vesicular stomatitis virus (VSV) particles, but the reagents and protocols are not widely available. Here, we detailed how to effectively pseudotype lentiviral particles with SARS-CoV-2 Spike and infect 293T cells engineered to express the SARS-CoV-2 receptor, ACE2. We also made all the key experimental reagents available in the BEI Resources repository of ATCC and the NIH. Furthermore, we demonstrated how these pseudotyped lentiviral particles could be used to measure the neutralizing activity of human sera or plasma against SARS-CoV-2 in convenient luciferase-based assays, thereby providing a valuable complement to ELISA-based methods that measure antibody binding rather than neutralization.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01AI141707, F30AI149928, HHSN272201700059C)
- National Institute of General Medical Sciences (R01GM120553)
- Pew Charitable Trusts (Pew Biomedical Scholars Award)
- Burroughs Wellcome Fund (Investigators in the Pathogenesis of Infectious Disease Award)
- National Institute on Drug Abuse (DP2DA040254)
- Howard Hughes Medical Institute (Investigator Research Budget)
This publication has 64 references indexed in Scilit:
- Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cellsBMC Biotechnology, 2013
- High Titer and Avidity of Nonneutralizing Antibodies against Influenza Vaccine Antigen Are Associated with Severe InfluenzaClinical and Vaccine Immunology, 2012
- Comparison of vesicular stomatitis virus pseudotyped with the S proteins from a porcine and a human coronavirusJournal of General Virology, 2009
- Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus ChallengeJournal of Virology, 2008
- The Cytoplasmic Tail of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains a Novel Endoplasmic Reticulum Retrieval Signal That Binds COPI and Promotes Interaction with Membrane ProteinJournal of Virology, 2007
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Retroviruses Pseudotyped with the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Efficiently Infect Cells Expressing Angiotensin-Converting Enzyme 2Journal of Virology, 2004
- The time course of the immune response to experimental coronavirus infection of manEpidemiology and Infection, 1990
- Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infectionEpidemiology and Infection, 1985
- The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: Evidence of heterogeneity among 229E‐related strainsJournal of Medical Virology, 1984